Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave to Submit HPV Study Results to FDA in April; Shares Jump

NEW YORK (GenomeWeb News) – Third Wave Technologies said yesterday after the close of the market that it will submit data from clinical trials on its human papillomavirus molecular diagnostic tests with the US Food and Drug Administration next month.
 
Investors responded enthusiastically to the news, sending Third Wave's shares up 33 percent to $9.45 in early Wednesday trade on the Nasdaq.
 
The Madison, Wis.-based firm said that its 14-type high-risk HPV test demonstrated a negative predictive value greater than 99 percent, which was the study’s goal. It said that it would provide further data from the study after its FDA submission.
 
The high-risk HPV test is intended to be used in combination with a Pap test to evaluate women aged 30 and over for the presence of high-risk HPV types and to guide treatment, said Third Wave.
 
Third Wave also intends to submit study data for its 16/18 HPV genotyping test, which it said achieved primary clinical endpoints, with the FDA next month. HPV types 16 and 18 have been implicated in 70 percent of cervical disease, according to Third Wave.
 
Third Wave said the global HPV testing market is projected to be $250 million in 2008. But the firm, and Qiagen, which sells the only FDA-cleared molecular test for HPV, believe the market is highly underpenetrated and could be valued at around $1 billion.
 
Separately this morning, First Analysis Securities upgraded its rating on Third Wave's stock to "overweight" from "equal-weight"

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.